Katherine K Thomas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5757517/publications.pdf

Version: 2024-02-01

50 papers

7,321 citations

147801 31 h-index 50 g-index

51 all docs 51 docs citations

51 times ranked 6970 citing authors

#	Article	IF	CITATIONS
1	High HIV incidence among young women in South Africa: Data from a large prospective study. PLoS ONE, 2022, 17, e0269317.	2.5	4
2	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Annals of Internal Medicine, 2021, 174, 344-352.	3.9	73
3	Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids). Contemporary Clinical Trials Communications, 2020, 20, 100673.	1.1	9
4	Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial. The Lancet Global Health, 2020, 8, e1305-e1315.	6.3	78
5	Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV,the, 2020, 7, e229-e237.	4.7	66
6	Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. Epidemics, 2018, 23, 34-41.	3.0	8
7	Antiretroviral Therapy Initiation Is Not Associated With Risky Sexual Behavior Among Heterosexual Human Immunodeficiency Virus–Infected Persons in Serodiscordant Partnerships. Sexually Transmitted Diseases, 2017, 44, 58-62.	1.7	8
8	Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 91-96.	2.1	6
9	Alignment of adherence and risk for HIV acquisition in a demonstration project of preâ€exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of preventionâ€effective adherence. Journal of the International AIDS Society, 2017, 20, 21842.	3.0	67
10	Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial. Journal of Infectious Diseases, 2016, 213, 551-555.	4.0	17
11	Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda. Lancet HIV,the, 2016, 3, e212-e220.	4.7	62
12	Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)–Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2–Coinfected Individuals. Journal of Infectious Diseases, 2016, 213, 1573-1578.	4.0	10
13	Host Genetic and Viral Determinants of HIV-1 RNA Set Point among HIV-1 Seroconverters from Sub-Saharan Africa. Journal of Virology, 2015, 89, 2104-2111.	3.4	22
14	Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infectious Diseases, The, 2014, 14, 1055-1064.	9.1	94
15	An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 522-529.	2.1	56
16	Mannose-binding lectin and ficolin-2 do not influence humoral immune response to hepatitis B vaccine. Vaccine, 2014, 32, 4772-4777.	3.8	3
17	Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infectious Diseases, The, 2013, 13, 1021-1028.	9.1	95
18	Standard Treatment Regimens for Nongonococcal Urethritis Have Similar but Declining Cure Rates: A Randomized Controlled Trial. Clinical Infectious Diseases, 2013, 56, 934-942.	5.8	166

#	Article	IF	CITATIONS
19	Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals. Aids, 2013, 27, 2155-2160.	2.2	124
20	Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. PLoS Medicine, 2013, 10, e1001511.	8.4	192
21	Partner Characteristics Predicting HIV-1 Set Point in Sexually Acquired HIV-1 Among African Seroconverters. AIDS Research and Human Retroviruses, 2013, 29, 164-171.	1.1	21
22	Extravaginal Reservoirs of Vaginal Bacteria as Risk Factors for Incident Bacterial Vaginosis. Journal of Infectious Diseases, 2012, 205, 1580-1588.	4.0	96
23	Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine, 2012, 367, 399-410.	27.0	2,665
24	Chlamydia Positivity in Women Screened in Family Planning Clinics: Racial/Ethnic Differences and Trends in the Northwest U.S., 1997–2006. Public Health Reports, 2012, 127, 38-51.	2.5	18
25	Effect of Sexual Activity on Vaginal Colonization With Hydrogen Peroxide-Producing Lactobacilli and Gardnerella vaginalis. Sexually Transmitted Diseases, 2011, 38, 1137-1144.	1.7	34
26	A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sexually Transmitted Infections, 2011, 87, 399-405.	1.9	31
27	Topical Penile Microbicide Use by Men to Prevent Recurrent Bacterial Vaginosis in Sex Partners: A Randomized Clinical Trial. Sexually Transmitted Diseases, 2011, 38, 483-489.	1.7	17
28	Genomewide Association Study for Determinants of HIV-1 Acquisition and Viral Set Point in HIV-1 Serodiscordant Couples with Quantified Virus Exposure. PLoS ONE, 2011, 6, e28632.	2.5	80
29	Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: a randomized clinical trial. Sexually Transmitted Diseases, 2011, 38, 483-9.	1.7	13
30	Temporal Variability of Human Vaginal Bacteria and Relationship with Bacterial Vaginosis. PLoS ONE, 2010, 5, e10197.	2.5	363
31	Risks for Acquisition of Bacterial Vaginosis Among Women Who Report Sex with Women: A Cohort Study. PLoS ONE, 2010, 5, e11139.	2.5	82
32	Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet, The, 2010, 375, 824-833.	13.7	142
33	Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet, The, 2010, 375, 2092-2098.	13.7	844
34	Prevalence and Risks for Bacterial Vaginosis in Women Who Have Sex With Women. Sexually Transmitted Diseases, 2010, 37, 335-339.	1.7	62
35	Expedited Partner Therapy: A Robust Intervention. Sexually Transmitted Diseases, 2010, 37, 602-607.	1.7	29
36	Prevalence and risks for bacterial vaginosis in women who have sex with women. Sexually Transmitted Diseases, 2010, 37, 335-9.	1.7	49

3

#	Article	IF	Citations
37	HIV Testing in a Highâ€Incidence Population: Is Antibody Testing Alone Good Enough?. Clinical Infectious Diseases, 2009, 49, 444-453.	5.8	125
38	Changes in Vaginal Bacterial Concentrations with Intravaginal Metronidazole Therapy for Bacterial Vaginosis as Assessed by Quantitative PCR. Journal of Clinical Microbiology, 2009, 47, 721-726.	3.9	141
39	Determinants of Recent HIV Infection Among Seattle-Area Men Who Have Sex with Men. American Journal of Public Health, 2009, 99, S157-S164.	2.7	57
40	Reduced Adipogenic Gene Expression in Thigh Adipose Tissue Precedes Human Immunodeficiency Virus-Associated Lipoatrophy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 959-966.	3.6	17
41	Relationship of Specific Vaginal Bacteria and Bacterial Vaginosis Treatment Failure in Women Who Have Sex with Women. Annals of Internal Medicine, 2008, 149, 20.	3.9	146
42	Safety, Acceptability, and Tolerability of 3 Topical Microbicides Among Heterosexual Kenyan Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 423-428.	2.1	7
43	Targeted PCR for Detection of Vaginal Bacteria Associated with Bacterial Vaginosis. Journal of Clinical Microbiology, 2007, 45, 3270-3276.	3.9	328
44	Using nurses to identify HAART eligible patients in the Republic of Mozambique: results of a time series analysis. Human Resources for Health, 2007, 5, 7.	3.1	27
45	Effect of Expedited Treatment of Sex Partners on Recurrent or Persistent Gonorrhea or Chlamydial Infection. New England Journal of Medicine, 2005, 352, 676-685.	27.0	434
46	Why Do Different Criteria for â€~Cure' Yield Different Conclusions in Comparing Two Treatments for Bacterial Vaginosis?. Sexually Transmitted Diseases, 2005, 32, 526-530.	1.7	8
47	Performance of a New, Rapid Assay for Detection of Trichomonas vaginalis. Journal of Clinical Microbiology, 2004, 42, 2940-2943.	3.9	42
48	Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: A randomized controlled trial. American Journal of Obstetrics and Gynecology, 2004, 191, 1898-1906.	1.3	80
49	Cervical Shedding of Human T Cell Lymphotropic Virus Type I Is Associated with Cervicitis. Journal of Infectious Diseases, 2002, 186, 1669-1672.	4.0	34
50	Concurrent and Sequential Acquisition of Different Genital Human Papillomavirus Types. Journal of Infectious Diseases, 2000, 182, 1097-1102.	4.0	169